ORIGINAL RESEARCH article

Front. Allergy

Sec. Asthma

Actual use of PROMs in Asthma and Rhinitis recommended by guidelines in clinical settings: PROMUSE Respiratory Study

  • 1. Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität zu Berlin, Berlin, Germany

  • 2. Fraunhofer-Institut fur Translationale Medizin und Pharmakologie ITMP, Frankfurt, Germany

  • 3. Universidad de Especialidades Espiritu Santo, Samborondon, Ecuador

  • 4. Respiralab Research Group, Guayaquil, Ecuador

  • 5. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

  • 6. Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Secenova Fakul'tet dovuzovskogo obrazovania, Moscow, Russia

  • 7. 7 State Budgetary Healthcare Institution of the City of Moscow "City Polyclinic No. 210 of the Department of Health of the City of Moscow", Moscow, Russia

  • 8. Federal State Budgetary Scientific Institution “N.A. Semashko National Research Institute of Public Health", Moscow, Russia

  • 9. Russian Medical Academy of Сontinuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia

  • 10. Institutul de Pneumoftiziologie Marius Nasta, Bucharest, Romania

  • 11. Kuwait University Faculty of Medicine, Safat, Kuwait

  • 12. Al-Rashed Allergy Center, Ministry of Health, Kuwait, Kuwait

  • 13. Hospital Espanol, Mexico City, Mexico

  • 14. Colegio Mexicano de Pediatras Especialistes en Inmunologia Clinica y Alergia AC, Distrito Federal, Mexico

  • 15. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

  • 16. Tbilisi David Agmasenebeli Teaching University, Tbilisi, Georgia

  • 17. Medica Sur, Mexico City, Mexico

  • 18. Univerzitetna klinika za pljucne bolezni in alergijo Golnik, Golnik, Slovenia

  • 19. Servicio de Alergia e Immunologia Clinica Santa Isabel Buenos Aires, Buenos Aires, Argentina

  • 20. Universidade Federal de Sao Paulo Disciplina de Alergia Imunologia Clinica e Reumatologia, São Paulo, Brazil

  • 21. Universidade Federal do Parana Departamento de Pediatria, Curitiba, Brazil

  • 22. Vilniaus universitetas Medicinos fakultetas, Vilnius, Lithuania

  • 23. Centro de Alergia Tinoco, Machala, Ecuador

  • 24. MASK-air SAS, Montpellier, France

  • 25. Universidad Estatal de Milagro, Milagro, Ecuador

  • 26. Ecuadorian Development Research Lab, Daule, Ecuador

  • 27. Philipps-Universitat Marburg, Marburg, Germany

Article metrics

View details

168

Views

The final, formatted version of the article will be published soon.

Abstract

Rationale: Guidelines advise for the implementation of patient-reported outcomes (PROMs) to provide crucial insights into patients' perceptions of their disease burden, treatment needs, and quality of life. Despite their proven benefits in managing chronic respiratory diseases like asthma, allergic rhinitis (AR), and rhinosinusitis (RS), there is limited data on their adoption among physicians treating these conditions. Objectives: Our objective is to identify the utilization patterns of PROMs, together with the reasons for their usage and the barriers to their adoption among practitioners managing patients with asthma, AR, and RS. Methods: This was a cross-sectional observational study using a questionnaire encompassing all pertinent PROMs and disseminated to practitioners associated with the ARIA, UCARE, ADCARE, and ACARE networks. Individuals unfamiliar with PROMS or lacking prior experience with it were eliminated. Descriptive and analytical data were utilized, categorized by the frequency and type of PROMs applied. Stata 18.0 was utilized, with p<0.05 indicating statistical significance. Results: A total of 439 practitioners participated, with PROMs predominantly utilized by physicians certified for over 30 years and by respiratory specialists (16.67% and 12.46%, respectively; p<0.05). Pulmonologists exhibited the greatest utilization of asthma PROMs at 86%, while allergists predominantly employed AR and RS PROMs at 38.42% and 33.33%, respectively (p < 0.001). ACT (66.74%), RCAT (27.79%), and SNOTT22 (15.26%) were the predominant PROMs utilized primarily for asthma (79.19%), AR (51.23%), and RS (57.26%), respectively (p<0.001). The foremost purposes for their application were disease control monitoring (93.39%) and evaluation of performance of therapy approaches (90.2%). The most significant barrier identified was time constraint, rated at 75.40% (p>0.05 across all groups). Conclusions: The use of PROMs is suboptimal, primarily due to time limitations. It is imperative that methods be swiftly implemented to include these techniques into the therapeutic environment to attain enhanced outcomes.

Summary

Keywords

allergic rhinitis, Asthma, Patient reported outcome measures, Physicians, rhinosinusitis

Received

15 July 2025

Accepted

31 January 2026

Copyright

© 2026 Cherrez-Ojeda, Bousquet, Zuberbier, Calderon, Kolkhir, Allenova, Allenov, Tkachenko, Florin, Ruxandra, Al-Ahmad, RODRIGUEZ-GONZALEZ, Wakida-Kusunoki, Ramon, Rukhadze, Larenas-Linnemann, Kosnik, Ivancevich, ENSINA, Augusto Rosario Filho, Kvedariene, Chong-Neto, Tinoco, Bedbrook, Rodas-Valero, Faytong-Haro, Maurer, Pfaar and Robles-Velasco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Iván Cherrez-Ojeda

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics